Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nitrofurantoin/Macrocrystals · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg |
| 2 | ACTIVE_COMPARATOR | Macrobid® Capsules 100 mg |
| Name | Type | Description |
|---|---|---|
| Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg | DRUG | 100mg, single dose fed |
| Macrobid® Capsules 100 mg | DRUG | 100mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum Beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to of the study and on the evening prior to e...
Nitrofurantoin/Macrocrystals is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is also known as Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg. The drug has been studied in Phase 1 clinical trials, with two completed trials involving a total of 151 healthy participants.
Nitrofurantoin/Macrocrystals is developed by Viatris Inc., which trades under the ticker VTRS. Viatris is the company responsible for the development of this drug candidate.
Nitrofurantoin/Macrocrystals is in Phase 1 clinical development. Two Phase 1 trials have been completed, and there are currently no active trials. The drug is investigational and has not been approved by the FDA for any indication.
Nitrofurantoin/Macrocrystals has been evaluated in two completed Phase 1 trials: NCT01018342, which enrolled 80 healthy volunteers, and NCT00649285, which enrolled 71 healthy volunteers. Both trials were conducted in the United States and were active-controlled, randomized studies.